Monkeypox Vaccine and Treatment Market Size, Share, By Product Type (Vaccine (JYNNEOS/ Imvanex, Smallpox Vaccine, Others), Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others), and Vaccinia Immune Globulin), By Gender Type (Male, Female, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others (Government agencies)), and By Region - Trends, Analysis and Forecast till 2034

By Region, the Monkeypox Vaccine and Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. 

The North American monkeypox vaccine market is major pharmaceutical companies, advanced healthcare infrastructure, and considerable government investment in vaccine research activities and its regional stockpiling. In the wake of these recent outbreaks, the U.S.A. and Canada presented broad-based vaccination plans. These countries also pivot on advanced regulatory frameworks, which have great flexibility while allowing fast approval and prompt distribution of vaccination programs. Moreover, North America is also home to significant vaccine manufacturers, leading to the region's domination.

In recent times, the cases of monkeypox in Europe have surged, subsequently increasing the demand for vaccines against the disease. The European Union, through its agency EMA, has successfully decided to fast-track the monkeypox vaccine authorization, ensuring that it covers all the member states. There has been a move in individual European countries to increase public health campaigns to help drive vaccine uptake, with countries investing in strategic vaccine reserves. In addressing the monkey-pox outbreak, vaccines have been available through agreements between governments, healthcare providers, and pharmaceutical companies in Europe.